|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ANXA2R |
Gene summary for ANXA2R |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ANXA2R | Gene ID | 389289 |
| Gene name | annexin A2 receptor | |
| Gene Alias | AX2R | |
| Cytomap | 5p12 | |
| Gene Type | protein-coding | GO ID | GO:0003674 | UniProtAcc | Q3ZCQ2 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 389289 | ANXA2R | LZE4T | Human | Esophagus | ESCC | 6.35e-03 | 9.57e-02 | 0.0811 |
| 389289 | ANXA2R | LZE5T | Human | Esophagus | ESCC | 1.48e-05 | 4.41e-01 | 0.0514 |
| 389289 | ANXA2R | LZE22D1 | Human | Esophagus | HGIN | 1.24e-04 | 2.31e-01 | 0.0595 |
| 389289 | ANXA2R | LZE22T | Human | Esophagus | ESCC | 1.54e-04 | 4.89e-01 | 0.068 |
| 389289 | ANXA2R | LZE24T | Human | Esophagus | ESCC | 9.19e-06 | 2.27e-01 | 0.0596 |
| 389289 | ANXA2R | LZE6T | Human | Esophagus | ESCC | 7.09e-15 | 5.54e-01 | 0.0845 |
| 389289 | ANXA2R | P4T-E | Human | Esophagus | ESCC | 9.91e-08 | 2.48e-01 | 0.1323 |
| 389289 | ANXA2R | P5T-E | Human | Esophagus | ESCC | 5.26e-03 | 5.50e-02 | 0.1327 |
| 389289 | ANXA2R | P9T-E | Human | Esophagus | ESCC | 2.00e-31 | 6.16e-01 | 0.1131 |
| 389289 | ANXA2R | P10T-E | Human | Esophagus | ESCC | 7.98e-13 | 2.48e-01 | 0.116 |
| 389289 | ANXA2R | P11T-E | Human | Esophagus | ESCC | 3.75e-08 | 3.11e-01 | 0.1426 |
| 389289 | ANXA2R | P17T-E | Human | Esophagus | ESCC | 4.48e-07 | 2.74e-01 | 0.1278 |
| 389289 | ANXA2R | P20T-E | Human | Esophagus | ESCC | 8.62e-07 | 1.59e-01 | 0.1124 |
| 389289 | ANXA2R | P23T-E | Human | Esophagus | ESCC | 2.37e-12 | 2.65e-01 | 0.108 |
| 389289 | ANXA2R | P24T-E | Human | Esophagus | ESCC | 8.84e-05 | 1.38e-01 | 0.1287 |
| 389289 | ANXA2R | P26T-E | Human | Esophagus | ESCC | 9.65e-09 | 1.60e-01 | 0.1276 |
| 389289 | ANXA2R | P27T-E | Human | Esophagus | ESCC | 2.06e-08 | 1.37e-01 | 0.1055 |
| 389289 | ANXA2R | P28T-E | Human | Esophagus | ESCC | 5.23e-07 | 9.90e-02 | 0.1149 |
| 389289 | ANXA2R | P30T-E | Human | Esophagus | ESCC | 2.13e-03 | 1.36e-01 | 0.137 |
| 389289 | ANXA2R | P32T-E | Human | Esophagus | ESCC | 8.27e-09 | 1.60e-01 | 0.1666 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ANXA2R | SNV | Missense_Mutation | c.197G>A | p.Gly66Glu | p.G66E | Q3ZCQ2 | protein_coding | tolerated(0.26) | benign(0.075) | TCGA-EK-A2RJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| ANXA2R | SNV | Missense_Mutation | c.121T>C | p.Tyr41His | p.Y41H | Q3ZCQ2 | protein_coding | deleterious(0) | possibly_damaging(0.662) | TCGA-CA-6718-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | PD | |
| ANXA2R | SNV | Missense_Mutation | c.371N>T | p.Ser124Ile | p.S124I | Q3ZCQ2 | protein_coding | tolerated(0.32) | benign(0.01) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| ANXA2R | SNV | Missense_Mutation | novel | c.293N>C | p.Lys98Thr | p.K98T | Q3ZCQ2 | protein_coding | tolerated(0.34) | possibly_damaging(0.451) | TCGA-AX-A06F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
| ANXA2R | SNV | Missense_Mutation | novel | c.275N>T | p.Ser92Ile | p.S92I | Q3ZCQ2 | protein_coding | tolerated(0.42) | benign(0.01) | TCGA-AX-A1CF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxifen | PD |
| ANXA2R | SNV | Missense_Mutation | novel | c.103C>T | p.Pro35Ser | p.P35S | Q3ZCQ2 | protein_coding | deleterious(0.04) | possibly_damaging(0.737) | TCGA-EO-A22U-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ANXA2R | SNV | Missense_Mutation | novel | c.40N>A | p.Asp14Asn | p.D14N | Q3ZCQ2 | protein_coding | tolerated(0.27) | benign(0.32) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
| ANXA2R | SNV | Missense_Mutation | novel | c.104N>G | p.Pro35Arg | p.P35R | Q3ZCQ2 | protein_coding | tolerated(0.09) | possibly_damaging(0.597) | TCGA-DD-AACP-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| ANXA2R | SNV | Missense_Mutation | novel | c.143C>T | p.Ser48Leu | p.S48L | Q3ZCQ2 | protein_coding | tolerated(0.08) | benign(0.204) | TCGA-MP-A4TI-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| ANXA2R | SNV | Missense_Mutation | rs754645658 | c.514N>T | p.Val172Phe | p.V172F | Q3ZCQ2 | protein_coding | deleterious_low_confidence(0.03) | possibly_damaging(0.859) | TCGA-NJ-A4YQ-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |